ZIM
TEVA icon

Zacks Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Zacks Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,530
Closed -$239K – 747
2014
Q1 		$239K Sell
4,530
-470
-9% -$21.7K 0.01% 590
2013
Q4 		$200K Sell
5,000
-186,454
-97% -$7.34M 0.01% 646
2013
Q3 		$7.23M Buy
191,454
+49,527
+35% +$1.93M 0.31% 122
2013
Q2 		$5.56M Buy
+141,927
New +$5.53M 0.26% 137

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Zacks Investment Management's TEVA Position: Q2 2014 in Review

Zacks Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 4,530 shares — an estimated $239K sold.

Zacks Investment Management first reported a position in TEVA in Q2 2013 and held it in 4 quarters. The position peaked at $7.23M in Q3 2013. 779 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • Zacks Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Zacks Investment Management sold 4,530 Teva Pharmaceuticals shares in Q2 2014, an estimated $239K.
  • Zacks Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Zacks Investment Management's Teva Pharmaceuticals position peaked at $7.23M in Q3 2013.
  • 779 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on Zacks Investment Management's 13F filing for Q2 2014, filed 12 Aug 2014.